Comparison · NCT04767373-567a0731
RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated Hospitalization
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated Hospitalization. Trial comparisons, record NCT04767373-567a0731. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04767373-567a0731
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00375 | 0.00198 | 0.00712 | wilson | |
| Risk in group 2 | 0.0233 | 0.0162 | 0.0335 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0196 | -0.0299 | -0.0117 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.161 | 0.0762 | 0.34 | log | |
| Odds ratio, group 1 over group 2 | 0.158 | 0.0742 | 0.336 | log | |
| Number needed to treat, for one fewer participant with the outcome on RSV Season 1: Clesrovimab 105 mg than on RSV Season 1: Placebo | 51.1 | 33.5 | 85.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RSV Season 1: Clesrovimab 105 mg | Participants received a single intramuscular (IM) administration of clesrovimab 105 mg on Day 1. | 9 | 2,398 | OG000 |
| Group 2 | RSV Season 1: Placebo | Participants received a single IM administration of placebo on Day 1. | 28 | 1,201 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- RSV Season 1: Number of Participants With RSV-Associated Hospitalization
- Description
RSV-associated hospitalization is defined as a hospital admission for respiratory illness and RSV-positive RT-PCR nasopharyngeal sample. Per protocol, the number of participants with RSV-associated hospitalization were reported for RSV season 1.
- Time frame
- From Day 1 (postdose) to Day 150
- Population
- All randomized participants who received a dose of study treatment and were protocol compliant.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
- NCT number
- NCT04767373
- Phases
- PHASE2, PHASE3
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Clesrovimab, Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2025-02-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04767373?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04767373-567a0731